APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metformin-Pioglitazone

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metformin-Pioglitazone Market Analysis and Forecast 2026-2032

22 December 2025191 pages

Choose your research edition.

Industry ResearchMetformin-Pioglitazone Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Metformin-Pioglitazone Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Metformin-Pioglitazone Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metformin-Pioglitazone Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Metformin-Pioglitazone Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Metformin-Pioglitazone market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Metformin-Pioglitazone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metformin-Pioglitazone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metformin-Pioglitazone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metformin-Pioglitazone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Metformin-Pioglitazone include Takeda Pharmaceuticals, Teva, Sandoz, Mylan, Wellona Pharma, Torrent Pharmaceuticals, Neurocon Inc, MACLEODS and BLUE CROSS, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Metformin-Pioglitazone, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metformin-Pioglitazone, also provides the revenue of main regions and countries. Of the upcoming market potential for Metformin-Pioglitazone, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metformin-Pioglitazone revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metformin-Pioglitazone market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Metformin-Pioglitazone revenue, projected growth trends, production technology, application and end-user industry.

Metformin-Pioglitazone Segment by Company

Takeda Pharmaceuticals

Teva

Sandoz

Mylan

Wellona Pharma

Torrent Pharmaceuticals

Neurocon Inc

MACLEODS

BLUE CROSS

Aurobindo Pharma

Metformin-Pioglitazone Segment by Type

Tablets: 15 mg pioglitazone/1000 mg metformin HCl

Tablets: 30 mg pioglitazone/1000 mg metformin HCl

Metformin-Pioglitazone Segment by Application

Hospital

Drug store

Metformin-Pioglitazone Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metformin-Pioglitazone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metformin-Pioglitazone and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metformin-Pioglitazone.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Metformin-Pioglitazone in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Metformin-Pioglitazone company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metformin-Pioglitazone revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metformin-Pioglitazone Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablets: 15 mg pioglitazone/1000 mg metformin HCl Major Player Table 3. Tablets: 30 mg pioglitazone/1000 mg metformin HCl Major Player Table 4. Global Metformin-Pioglitazone Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Drug store Major Player Table 7. Metformin-Pioglitazone Industry Trends Table 8. Metformin-Pioglitazone Industry Drivers Table 9. Metformin-Pioglitazone Industry Opportunities and Challenges Table 10. Metformin-Pioglitazone Industry Restraints Table 11. Global Metformin-Pioglitazone Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Metformin-Pioglitazone Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Metformin-Pioglitazone Market Share by Region (2021-2026) Table 14. Global Metformin-Pioglitazone Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Metformin-Pioglitazone Market Share by Region (2027-2032) Table 16. Global Metformin-Pioglitazone Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Metformin-Pioglitazone Revenue Market Share by Players (2021-2026) Table 18. Global Metformin-Pioglitazone Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Metformin-Pioglitazone Key Players Headquarters & Area Served Table 20. Global Metformin-Pioglitazone Players, Product Type & Application Table 21. Global Metformin-Pioglitazone Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Metformin-Pioglitazone by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Metformin-Pioglitazone Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Metformin-Pioglitazone Revenue Market Share by Type (2021-2026) Table 28. Global Metformin-Pioglitazone Revenue Market Share by Type (2027-2032) Table 29. Global Metformin-Pioglitazone Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Metformin-Pioglitazone Revenue Market Share by Application (2021-2026) Table 33. Global Metformin-Pioglitazone Revenue Market Share by Application (2027-2032) Table 34. Takeda Pharmaceuticals Company Information Table 35. Takeda Pharmaceuticals Business Overview Table 36. Takeda Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Takeda Pharmaceuticals Metformin-Pioglitazone Product Portfolio Table 38. Takeda Pharmaceuticals Recent Development Table 39. Teva Company Information Table 40. Teva Business Overview Table 41. Teva Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Teva Metformin-Pioglitazone Product Portfolio Table 43. Teva Recent Development Table 44. Sandoz Company Information Table 45. Sandoz Business Overview Table 46. Sandoz Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Sandoz Metformin-Pioglitazone Product Portfolio Table 48. Sandoz Recent Development Table 49. Mylan Company Information Table 50. Mylan Business Overview Table 51. Mylan Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Mylan Metformin-Pioglitazone Product Portfolio Table 53. Mylan Recent Development Table 54. Wellona Pharma Company Information Table 55. Wellona Pharma Business Overview Table 56. Wellona Pharma Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Wellona Pharma Metformin-Pioglitazone Product Portfolio Table 58. Wellona Pharma Recent Development Table 59. Torrent Pharmaceuticals Company Information Table 60. Torrent Pharmaceuticals Business Overview Table 61. Torrent Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Torrent Pharmaceuticals Metformin-Pioglitazone Product Portfolio Table 63. Torrent Pharmaceuticals Recent Development Table 64. Neurocon Inc Company Information Table 65. Neurocon Inc Business Overview Table 66. Neurocon Inc Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Neurocon Inc Metformin-Pioglitazone Product Portfolio Table 68. Neurocon Inc Recent Development Table 69. MACLEODS Company Information Table 70. MACLEODS Business Overview Table 71. MACLEODS Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. MACLEODS Metformin-Pioglitazone Product Portfolio Table 73. MACLEODS Recent Development Table 74. BLUE CROSS Company Information Table 75. BLUE CROSS Business Overview Table 76. BLUE CROSS Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. BLUE CROSS Metformin-Pioglitazone Product Portfolio Table 78. BLUE CROSS Recent Development Table 79. Aurobindo Pharma Company Information Table 80. Aurobindo Pharma Business Overview Table 81. Aurobindo Pharma Metformin-Pioglitazone Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Aurobindo Pharma Metformin-Pioglitazone Product Portfolio Table 83. Aurobindo Pharma Recent Development Table 84. North America Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 87. North America Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 88. North America Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Metformin-Pioglitazone Revenue by Country (2021-2026) & (US$ Million) Table 90. North America Metformin-Pioglitazone Revenue by Country (US$ Million) & (2027-2032) Table 91. Europe Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 92. Europe Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 93. Europe Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 94. Europe Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 95. Europe Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Metformin-Pioglitazone Revenue by Country (2021-2026) & (US$ Million) Table 97. Europe Metformin-Pioglitazone Revenue by Country (US$ Million) & (2027-2032) Table 98. China Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 99. China Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 100. China Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 101. China Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 103. Asia Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 104. Asia Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 105. Asia Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Metformin-Pioglitazone Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Metformin-Pioglitazone Revenue by Region (US$ Million) & (2021-2026) Table 108. Asia Metformin-Pioglitazone Revenue by Region (US$ Million) & (2027-2032) Table 109. SAMEA Metformin-Pioglitazone Revenue by Type (2021-2026) & (US$ Million) Table 110. SAMEA Metformin-Pioglitazone Revenue by Type (2027-2032) & (US$ Million) Table 111. SAMEA Metformin-Pioglitazone Revenue by Application (2021-2026) & (US$ Million) Table 112. SAMEA Metformin-Pioglitazone Revenue by Application (2027-2032) & (US$ Million) Table 113. SAMEA Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. SAMEA Metformin-Pioglitazone Revenue by Country (2021-2026) & (US$ Million) Table 115. SAMEA Metformin-Pioglitazone Revenue by Country (US$ Million) & (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Metformin-Pioglitazone Image Figure 2. Global Metformin-Pioglitazone Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metformin-Pioglitazone Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablets: 15 mg pioglitazone/1000 mg metformin HCl Image Figure 5. Tablets: 30 mg pioglitazone/1000 mg metformin HCl Image Figure 6. Global Metformin-Pioglitazone Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Metformin-Pioglitazone Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Drug store Image Figure 10. Global Metformin-Pioglitazone Market Size (US$ Million) & (2021-2032) Figure 11. Global Metformin-Pioglitazone Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Metformin-Pioglitazone Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Metformin-Pioglitazone Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Metformin-Pioglitazone Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Metformin-Pioglitazone Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Metformin-Pioglitazone Revenue Market Share by Type (2021-2032) Figure 18. Global Metformin-Pioglitazone Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Metformin-Pioglitazone Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Metformin-Pioglitazone Revenue Market Share by Application (2021-2032) Figure 21. North America Metformin-Pioglitazone Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Metformin-Pioglitazone Revenue Share by Type (2021-2032) Figure 23. North America Metformin-Pioglitazone Revenue Share by Application (2021-2032) Figure 24. North America Metformin-Pioglitazone Revenue Share by Country (2021-2032) Figure 25. United States Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Metformin-Pioglitazone Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Metformin-Pioglitazone Revenue Share by Type (2021-2032) Figure 30. Europe Metformin-Pioglitazone Revenue Share by Application (2021-2032) Figure 31. Europe Metformin-Pioglitazone Revenue Share by Country (2021-2032) Figure 32. Germany Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Metformin-Pioglitazone Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Metformin-Pioglitazone Revenue Share by Type (2021-2032) Figure 42. China Metformin-Pioglitazone Revenue Share by Application (2021-2032) Figure 43. Asia Metformin-Pioglitazone Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Metformin-Pioglitazone Revenue Share by Type (2021-2032) Figure 45. Asia Metformin-Pioglitazone Revenue Share by Application (2021-2032) Figure 46. Asia Metformin-Pioglitazone Revenue Share by Region (2021-2032) Figure 47. Japan Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Metformin-Pioglitazone Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Metformin-Pioglitazone Revenue Share by Type (2021-2032) Figure 55. SAMEA Metformin-Pioglitazone Revenue Share by Application (2021-2032) Figure 56. SAMEA Metformin-Pioglitazone Revenue Share by Country (2021-2032) Figure 57. Brazil Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Metformin-Pioglitazone Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets: 15 mg pioglitazone/1000 mg metformin HCl
  • Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Applications
  • Hospital
  • Drug store
Companies covered
  • Takeda Pharmaceuticals
  • Teva
  • Sandoz
  • Mylan
  • Wellona Pharma
  • Torrent Pharmaceuticals
  • Neurocon Inc
  • MACLEODS
  • BLUE CROSS
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metformin-Pioglitazone Market by Type
  3. 1.2.1 Global Metformin-Pioglitazone Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablets: 15 mg pioglitazone/1000 mg metformin HCl
  5. 1.2.3 Tablets: 30 mg pioglitazone/1000 mg metformin HCl
  6. 1.3 Metformin-Pioglitazone Market by Application
  7. 1.3.1 Global Metformin-Pioglitazone Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Drug store
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Metformin-Pioglitazone Market Dynamics
  1. 2.1 Metformin-Pioglitazone Industry Trends
  2. 2.2 Metformin-Pioglitazone Industry Drivers
  3. 2.3 Metformin-Pioglitazone Industry Opportunities and Challenges
  4. 2.4 Metformin-Pioglitazone Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Metformin-Pioglitazone Market Perspective (2021-2032)
  2. 3.2 Global Metformin-Pioglitazone Growth Trends by Region
  3. 3.2.1 Global Metformin-Pioglitazone Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metformin-Pioglitazone Market Size by Region (2021-2026)
  5. 3.2.3 Global Metformin-Pioglitazone Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Metformin-Pioglitazone Revenue by Players
  2. 4.1.1 Global Metformin-Pioglitazone Revenue by Players (2021-2026)
  3. 4.1.2 Global Metformin-Pioglitazone Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Metformin-Pioglitazone Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metformin-Pioglitazone Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Metformin-Pioglitazone Key Players Headquarters & Area Served
  7. 4.4 Global Metformin-Pioglitazone Players, Product Type & Application
  8. 4.5 Global Metformin-Pioglitazone Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Metformin-Pioglitazone Market CR5 and HHI
  11. 4.6.3 2025 Metformin-Pioglitazone Tier 1, Tier 2, and Tier 3
5 Metformin-Pioglitazone Market Size by Type
  1. 5.1 Global Metformin-Pioglitazone Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 5.3 Global Metformin-Pioglitazone Revenue Market Share by Type (2021-2032)
6 Metformin-Pioglitazone Market Size by Application
  1. 6.1 Global Metformin-Pioglitazone Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Metformin-Pioglitazone Revenue by Application (2021-2032)
  3. 6.3 Global Metformin-Pioglitazone Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals
  2. 7.1.1 Takeda Pharmaceuticals Company Information
  3. 7.1.2 Takeda Pharmaceuticals Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Metformin-Pioglitazone Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Metformin-Pioglitazone Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sandoz
  14. 7.3.1 Sandoz Company Information
  15. 7.3.2 Sandoz Business Overview
  16. 7.3.3 Sandoz Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sandoz Metformin-Pioglitazone Product Portfolio
  18. 7.3.5 Sandoz Recent Developments
  19. 7.4 Mylan
  20. 7.4.1 Mylan Company Information
  21. 7.4.2 Mylan Business Overview
  22. 7.4.3 Mylan Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Mylan Metformin-Pioglitazone Product Portfolio
  24. 7.4.5 Mylan Recent Developments
  25. 7.5 Wellona Pharma
  26. 7.5.1 Wellona Pharma Company Information
  27. 7.5.2 Wellona Pharma Business Overview
  28. 7.5.3 Wellona Pharma Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Wellona Pharma Metformin-Pioglitazone Product Portfolio
  30. 7.5.5 Wellona Pharma Recent Developments
  31. 7.6 Torrent Pharmaceuticals
  32. 7.6.1 Torrent Pharmaceuticals Company Information
  33. 7.6.2 Torrent Pharmaceuticals Business Overview
  34. 7.6.3 Torrent Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Torrent Pharmaceuticals Metformin-Pioglitazone Product Portfolio
  36. 7.6.5 Torrent Pharmaceuticals Recent Developments
  37. 7.7 Neurocon Inc
  38. 7.7.1 Neurocon Inc Company Information
  39. 7.7.2 Neurocon Inc Business Overview
  40. 7.7.3 Neurocon Inc Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Neurocon Inc Metformin-Pioglitazone Product Portfolio
  42. 7.7.5 Neurocon Inc Recent Developments
  43. 7.8 MACLEODS
  44. 7.8.1 MACLEODS Company Information
  45. 7.8.2 MACLEODS Business Overview
  46. 7.8.3 MACLEODS Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  47. 7.8.4 MACLEODS Metformin-Pioglitazone Product Portfolio
  48. 7.8.5 MACLEODS Recent Developments
  49. 7.9 BLUE CROSS
  50. 7.9.1 BLUE CROSS Company Information
  51. 7.9.2 BLUE CROSS Business Overview
  52. 7.9.3 BLUE CROSS Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BLUE CROSS Metformin-Pioglitazone Product Portfolio
  54. 7.9.5 BLUE CROSS Recent Developments
  55. 7.10 Aurobindo Pharma
  56. 7.10.1 Aurobindo Pharma Company Information
  57. 7.10.2 Aurobindo Pharma Business Overview
  58. 7.10.3 Aurobindo Pharma Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Aurobindo Pharma Metformin-Pioglitazone Product Portfolio
  60. 7.10.5 Aurobindo Pharma Recent Developments
8 North America
  1. 8.1 North America Metformin-Pioglitazone Revenue (2021-2032)
  2. 8.2 North America Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 8.2.1 North America Metformin-Pioglitazone Revenue by Type (2021-2026)
  4. 8.2.2 North America Metformin-Pioglitazone Revenue by Type (2027-2032)
  5. 8.3 North America Metformin-Pioglitazone Revenue Share by Type (2021-2032)
  6. 8.4 North America Metformin-Pioglitazone Revenue by Application (2021-2032)
  7. 8.4.1 North America Metformin-Pioglitazone Revenue by Application (2021-2026)
  8. 8.4.2 North America Metformin-Pioglitazone Revenue by Application (2027-2032)
  9. 8.5 North America Metformin-Pioglitazone Revenue Share by Application (2021-2032)
  10. 8.6 North America Metformin-Pioglitazone Revenue by Country
  11. 8.6.1 North America Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Metformin-Pioglitazone Revenue by Country (2021-2026)
  13. 8.6.3 North America Metformin-Pioglitazone Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Metformin-Pioglitazone Revenue (2021-2032)
  2. 9.2 Europe Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 9.2.1 Europe Metformin-Pioglitazone Revenue by Type (2021-2026)
  4. 9.2.2 Europe Metformin-Pioglitazone Revenue by Type (2027-2032)
  5. 9.3 Europe Metformin-Pioglitazone Revenue Share by Type (2021-2032)
  6. 9.4 Europe Metformin-Pioglitazone Revenue by Application (2021-2032)
  7. 9.4.1 Europe Metformin-Pioglitazone Revenue by Application (2021-2026)
  8. 9.4.2 Europe Metformin-Pioglitazone Revenue by Application (2027-2032)
  9. 9.5 Europe Metformin-Pioglitazone Revenue Share by Application (2021-2032)
  10. 9.6 Europe Metformin-Pioglitazone Revenue by Country
  11. 9.6.1 Europe Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Metformin-Pioglitazone Revenue by Country (2021-2026)
  13. 9.6.3 Europe Metformin-Pioglitazone Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Metformin-Pioglitazone Revenue (2021-2032)
  2. 10.2 China Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 10.2.1 China Metformin-Pioglitazone Revenue by Type (2021-2026)
  4. 10.2.2 China Metformin-Pioglitazone Revenue by Type (2027-2032)
  5. 10.3 China Metformin-Pioglitazone Revenue Share by Type (2021-2032)
  6. 10.4 China Metformin-Pioglitazone Revenue by Application (2021-2032)
  7. 10.4.1 China Metformin-Pioglitazone Revenue by Application (2021-2026)
  8. 10.4.2 China Metformin-Pioglitazone Revenue by Application (2027-2032)
  9. 10.5 China Metformin-Pioglitazone Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metformin-Pioglitazone Revenue (2021-2032)
  2. 11.2 Asia Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 11.2.1 Asia Metformin-Pioglitazone Revenue by Type (2021-2026)
  4. 11.2.2 Asia Metformin-Pioglitazone Revenue by Type (2027-2032)
  5. 11.3 Asia Metformin-Pioglitazone Revenue Share by Type (2021-2032)
  6. 11.4 Asia Metformin-Pioglitazone Revenue by Application (2021-2032)
  7. 11.4.1 Asia Metformin-Pioglitazone Revenue by Application (2021-2026)
  8. 11.4.2 Asia Metformin-Pioglitazone Revenue by Application (2027-2032)
  9. 11.5 Asia Metformin-Pioglitazone Revenue Share by Application (2021-2032)
  10. 11.6 Asia Metformin-Pioglitazone Revenue by Country
  11. 11.6.1 Asia Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Metformin-Pioglitazone Revenue by Country (2021-2026)
  13. 11.6.3 Asia Metformin-Pioglitazone Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metformin-Pioglitazone Revenue (2021-2032)
  2. 12.2 SAMEA Metformin-Pioglitazone Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Metformin-Pioglitazone Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Metformin-Pioglitazone Revenue by Type (2027-2032)
  5. 12.3 SAMEA Metformin-Pioglitazone Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Metformin-Pioglitazone Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Metformin-Pioglitazone Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Metformin-Pioglitazone Revenue by Application (2027-2032)
  9. 12.5 SAMEA Metformin-Pioglitazone Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Metformin-Pioglitazone Revenue by Country
  11. 12.6.1 SAMEA Metformin-Pioglitazone Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Metformin-Pioglitazone Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Metformin-Pioglitazone Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst